DNA vaccination for prostate cancer: key concepts and considerations

Grace Cole, Joanne McCaffrey, Ahlam A Ali, Helen O McCarthy

Research output: Contribution to journalReview articlepeer-review

16 Citations (Scopus)
311 Downloads (Pure)


While locally confined prostate cancer is associated with a low five year mortality rate, advanced or metastatic disease remains a major challenge for healthcare professionals to treat and is usually terminal. As such, there is a need for the development of new, efficacious therapies for prostate cancer. Immunotherapy represents a promising approach where the host's immune system is harnessed to mount an anti-tumour effect, and the licensing of the first prostate cancer specific immunotherapy in 2010 has opened the door for other immunotherapies to gain regulatory approval. Among these strategies DNA vaccines are an attractive option in terms of their ability to elicit a highly specific, potent and wide-sweeping immune response. Several DNA vaccines have been tested for prostate cancer and while they have demonstrated a good safety profile they have faced problems with low efficacy and immunogenicity compared to other immunotherapeutic approaches. This review focuses on the positive aspects of DNA vaccines for prostate cancer that have been assessed in preclinical and clinical trials thus far and examines the key considerations that must be employed to improve the efficacy and immunogenicity of these vaccines.

Original languageEnglish
Article number2
JournalCancer Nanotechnology
Publication statusPublished - 02 Jul 2015


Dive into the research topics of 'DNA vaccination for prostate cancer: key concepts and considerations'. Together they form a unique fingerprint.

Cite this